- Home
- PAVM vs KPRX Comparison
PAVM vs KPRX Comparison
Compare PAVM & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- KPRX
- Stock Information
- Founded
- PAVM 2014
- KPRX 1998
- Country
- PAVM United States
- KPRX United States
- Employees
- PAVM N/A
- KPRX N/A
- Industry
- PAVM Medical/Dental Instruments
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PAVM Health Care
- KPRX Health Care
- Exchange
- PAVM Nasdaq
- KPRX Nasdaq
- Market Cap
- PAVM 8.0M
- KPRX 7.5M
- IPO Year
- PAVM 2016
- KPRX N/A
- Fundamental
- Price
- PAVM $0.46
- KPRX $2.50
- Analyst Decision
- PAVM Strong Buy
- KPRX Strong Buy
- Analyst Count
- PAVM 1
- KPRX 1
- Target Price
- PAVM $19.00
- KPRX $10.00
- AVG Volume (30 Days)
- PAVM 250.8K
- KPRX 76.9K
- Earning Date
- PAVM 08-14-2025
- KPRX 08-08-2025
- Dividend Yield
- PAVM N/A
- KPRX N/A
- EPS Growth
- PAVM N/A
- KPRX N/A
- EPS
- PAVM 0.96
- KPRX N/A
- Revenue
- PAVM $1,993,000.00
- KPRX N/A
- Revenue This Year
- PAVM N/A
- KPRX N/A
- Revenue Next Year
- PAVM $455.63
- KPRX N/A
- P/E Ratio
- PAVM $0.48
- KPRX N/A
- Revenue Growth
- PAVM N/A
- KPRX N/A
- 52 Week Low
- PAVM $0.30
- KPRX $2.25
- 52 Week High
- PAVM $1.90
- KPRX $4.29
- Technical
- Relative Strength Index (RSI)
- PAVM 35.35
- KPRX 34.42
- Support Level
- PAVM $0.43
- KPRX $2.27
- Resistance Level
- PAVM $0.53
- KPRX $2.60
- Average True Range (ATR)
- PAVM 0.05
- KPRX 0.15
- MACD
- PAVM -0.01
- KPRX -0.02
- Stochastic Oscillator
- PAVM 52.70
- KPRX 24.71
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.